Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Background<br/> Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. <br/><br/> Methods <...
| Автори: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Опубліковано: |
Lancet
2016
|